Community Practice Connections™: The Role of Anticoagulants for Secondary Prevention in Patients With CAD and PAD: When Should Therapy Be Initiated?

Released On
January 15, 2021

Expires On
January 15, 2022

Media Type
Internet

Completion Time
90 minutes

Specialty
Cardiology

Topic(s)
Cardiovascular Disease, Heart Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

Credit Available

  • Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is directed toward cardiologists and cardiology subspecialists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with CAD and PAD are invited to participate.

Activity Overview

This online virtual symposium brings renowned experts in atherosclerotic disease together to provide attendees with commentary on state-of-the-art management and prevention of coronary artery disease (CAD) and peripheral arterial disease (PAD), with antithrombotic strategies. Atherosclerosis is a key pathogenetic mechanism that underlies clinical conditions that account for the top causes of mortality and mortality among Americans—CAD and PAD. Despite advances in the care of patients with these diseases, opportunities remain to improve the delivery of care to affected patients through ongoing clinician education and professional development. Focus is placed on reducing the risk of secondary events in these patients. By coupling practice-focused, slide-based presentations with engaging patient-case vignettes, faculty highlight current recommendations that constitute best practices.

This Community Practice Connection™ program provides a review of some of the key highlights from a live virtual symposium held on November 17, 2020. This unique and engaging multimedia activity is ideal for the community-based clinician, as it helps to place recent clinical trial data within a clinical context. The program is designed for those who did not attend the live meeting and would help to reinforce learning for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of novel antithrombotic strategies in the secondary prevention setting
  • Identify strategies for reducing the risk of additional events in patients with existing CAD and PAD
  • Evaluate the efficacy and safety of antithrombotic strategies used to mitigate cardiovascular risk in patients with CAD and PAD

Faculty

FACULTY_NAME

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA

FACULTY_NAME

Kelley R. Branch, MD, MS

Associate Professor of Medicine
Director, Cardiovascular Clinical Trials
Associate Director, Clinical Trials Service Unit
Attending Physician
University of Washington Medical Center
Seattle, WA

FACULTY_NAME

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA

Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

  • Grant Research Support:: Research Funding: Amarin, Amgen, AstraZeneca, Bristol Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood Pharmaceuticals, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi, The Medicines Company

Kelley R. Branch, MD, MS

  • Grant Research Support: Bayer, Lilly, Sanofi; Consultant: Bayer, Janssen, Kestra Medical Technologies, Sana Biotechnology

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA

  • Consultant: Amgen, Sanofi, Boehringer Ingelheim, Janssen, Quantum Genomics

The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  1. Complete the activity (including pre-activity and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.